Pharmanovia is a leading lifecycle management company dedicated to maximizing the potential of established medicines. With a strong emphasis on patient and clinician insights, Pharmanovia identifies unmet medical needs and leverages its expertise in innovative life cycle management to enhance patient outcomes. The company boasts a diverse portfolio, featuring key products across various therapeutic areas, including cardiovascular medications like Inderal® and Zestril®, endocrinology treatments such as Bonviva®, neurology solutions like Anaprox® and Valium®, and oncology products including Bondronat® and Kytril®.

With over 25 brands in more than 160 markets, Pharmanovia operates from 15+ offices globally and employs around 320 professionals committed to improving health outcomes. The company actively partners with innovative pharmaceutical firms, digital health pioneers, and tech platforms to enhance the patient experience. As a member of Medicines for Europe, Pharmanovia is driven by a collaborative spirit and a commitment to sustainability, ensuring that their contributions positively impact both patients and the broader community.